MiniMed® Inc.
Premarket Notification - 510(k)
Paradigm™ Insulin Pump





Section D. 510(k) Summary

In accordance with the requirements of SMDA 1990, and 21 CFR 807.92, this 510(k) Summary is provided:

Submitter: MiniMed® Inc. 12744 San Fernando Rd., Sylmar, California 91342

Contact: Jennifer Lyons (818) 362-5958, Ext. 7381

Name of Device: MiniMed Paradigm™ Insulin Pump

Predicate Device: MiniMed Model 508 Insulin Pump

Description of the Device: The Paradigm external insulin pump is an ambulatory, battery operated, rate-programmable microinfusion pump, designed for continuous delivery of insulin. A custom reservoir is driven by a drive motor to deliver preset basal profiles and patient programmed bolus amounts of insulin through custom infusion sets into subcutaneous tissue. This pump incorporates improvements over the predicate model. The Paradigm pump is restricted to sale by, or on the order of, a physician.

Intended Use of the Device: The MiniMed Paradigm insulin pump is intended for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin.

Comparison of the Technological Features of the New Device and Predicate Device: The new and predicate devices have similar materials and basic design. The new device uses a different motor design and battery type relative to the predicate.

Jennifer Lyons

date

Regulatory Affairs Specialist

MiniMed Inc.

[®] MiniMed is a Registered Trademark of MiniMed Inc.

[™] Paradigm is a Trademark of MiniMed Inc.



AUG 1 8 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Jennifer Lyons Regulatory Affairs Specialist MiniMed, Incorporated 12744 San Fernando Road Sylmar, California 91342

Re: K001829

Trade Name: MiniMed Paradigm Insulin Pump, Model 511

Regulatory Class: II Product Code: FRN Dated: June 15, 2000 Received: June 16, 2000

Dear Ms. Lyons:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely\yours

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure



INDICATIONS FOR USE

510(k) Number:

Device Name:

MiniMed Paradigm™ Insulin Pump

Indications for Use:

The MiniMed Paradigm Insulin Pump is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring

insulin.

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Dental, Infection Control,

and General Hospital Devices

510(k) Number K00/8 Over-the-Counter Use

Prescription Use (Per 21 CFR 801.109)

r 21 CFR 801.109)